SFM
DRNA

Signet Financial Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Signet Financial Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-800
Closed -$8K – 1150
2018
Q1 		$8K Buy
+800
New +$8.63K ﹤0.01% 619

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Signet Financial Management's DRNA Position: Q2 2018 in Review

Signet Financial Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2018, closing a stake of 800 shares — an estimated $8K sold.

Signet Financial Management first reported a position in DRNA in Q1 2018 and held it in 1 quarter. The position peaked at $8K in Q1 2018. 85 funds tracked by Wall St. Rank hold DRNA as of Q2 2018.

  • Signet Financial Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Signet Financial Management sold 800 Dicerna Pharmaceuticals, Inc. shares in Q2 2018, an estimated $8K.
  • Signet Financial Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Signet Financial Management's Dicerna Pharmaceuticals, Inc. position peaked at $8K in Q1 2018.
  • 85 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2018.

Based on Signet Financial Management's 13F filing for Q2 2018, filed 10 Aug 2018.